LFST
LifeStance Health Group, Inc. NASDAQ Listed Jun 10, 2021$8.84
Mkt Cap $3.4B
52w Low $3.74
98.9% of range
52w High $8.89
50d MA $6.80
200d MA $6.16
P/E (TTM)
251.0x
EV/EBITDA
33.8x
P/B
1.9x
Debt/Equity
0.1x
ROE
0.6%
P/FCF
24.7x
RSI (14)
—
ATR (14)
—
Beta
1.13
50d MA
$6.80
200d MA
$6.16
Avg Volume
2.2M
LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates outpatient mental health platform as well as offers patients care virtually through its online delivery platform or in-person at its centers in 32 states. It serves children, adolescents, adults, and geriatrics. LifeStance Health Group, Inc. was founded in 2017 and is based in Scottsdale, Arizona.
4800 N. Scottsdale Road · Scottsdale, AZ 85251 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 7.36 | +8.7% | +20.2% | — | — | — | — | — |
| Feb 25, 2026 | AMC | -0.00 | 0.03 | +3287.2% | 7.41 | -5.8% | -6.1% | +4.0% | -1.4% | +1.8% | +0.8% | — |
| Nov 6, 2025 | AMC | -0.01 | 0.00 | +128.0% | 6.25 | +1.9% | +0.6% | +2.2% | +0.6% | -0.5% | -2.0% | — |
| Aug 7, 2025 | AMC | -0.03 | -0.01 | +66.7% | 3.86 | +1.8% | +13.2% | +4.6% | +2.0% | +10.9% | +7.9% | — |
| May 7, 2025 | AMC | -0.04 | 0.00 | +104.5% | 5.51 | +0.9% | +5.4% | -1.4% | +2.1% | +0.3% | -2.2% | — |
| Feb 27, 2025 | AMC | -0.04 | -0.02 | +50.0% | 7.74 | +1.2% | +0.6% | +1.5% | +1.4% | +1.7% | -3.4% | — |
| Nov 7, 2024 | AMC | -0.07 | -0.02 | +71.4% | 7.68 | +0.4% | -4.2% | +0.4% | +0.1% | -2.4% | +0.1% | — |
| Aug 8, 2024 | AMC | -0.07 | -0.06 | +14.3% | 5.93 | -2.9% | -5.6% | -1.8% | +6.2% | -2.7% | +2.8% | — |
| May 9, 2024 | AMC | -0.09 | -0.06 | +33.3% | 7.12 | +0.8% | -3.7% | +4.5% | +3.1% | +1.4% | -1.6% | — |
| Feb 28, 2024 | AMC | -0.09 | -0.12 | -33.3% | 8.71 | +1.4% | -4.1% | -6.7% | -0.4% | -4.9% | -1.9% | — |
| Nov 8, 2023 | AMC | -0.07 | -0.17 | -142.9% | 5.82 | +0.7% | -3.4% | -0.2% | +0.7% | +9.9% | -1.4% | — |
| Aug 9, 2023 | AMC | -0.09 | -0.13 | -44.4% | 8.06 | +0.6% | +2.4% | -1.1% | -1.5% | -0.7% | -4.0% | — |
| May 10, 2023 | AMC | -0.11 | -0.09 | +18.2% | 8.26 | +1.7% | -0.2% | +3.6% | -1.1% | -1.9% | -1.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 6 | Barclays | Maintains | Overweight → Overweight | — | $6.95 | $7.00 | +0.7% | -0.3% | -0.3% | -2.6% | -1.3% | -4.7% |
| Feb 26 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $7.41 | $6.98 | -5.8% | -6.1% | +4.0% | -1.4% | +1.8% | +0.8% |
| Feb 26 | Canaccord Genuity | Maintains | Buy → Buy | — | $7.41 | $6.98 | -5.8% | -6.1% | +4.0% | -1.4% | +1.8% | +0.8% |
| Feb 26 | UBS | Maintains | Buy → Buy | — | $7.41 | $6.98 | -5.8% | -6.1% | +4.0% | -1.4% | +1.8% | +0.8% |
| Feb 2 | BTIG | Maintains | Buy → Buy | — | $7.07 | $7.17 | +1.4% | +1.6% | -1.0% | -2.5% | -5.6% | +4.4% |
| Dec 12 | BTIG | Maintains | Buy → Buy | — | $6.76 | $6.83 | +1.0% | +2.2% | +0.1% | -0.6% | +0.4% | +0.4% |
| Nov 7 | UBS | Maintains | Buy → Buy | — | $6.25 | $6.37 | +1.9% | +0.6% | +2.2% | +0.6% | -0.5% | -2.0% |
| Nov 6 | BTIG | Maintains | Buy → Buy | — | $4.81 | $5.34 | +11.0% | +29.9% | +0.6% | +2.2% | +0.6% | -0.5% |
| Aug 8 | UBS | Maintains | Buy → Buy | — | $3.86 | $3.93 | +1.8% | +13.2% | +4.6% | +2.0% | +10.9% | +7.9% |
| May 27 | UBS | Upgrade | Neutral → Buy | — | $5.49 | $6.10 | +11.1% | +10.4% | -0.3% | -2.2% | +0.5% | -1.0% |
| Dec 16 | Goldman Sachs | Upgrade | Neutral → Buy | — | $7.17 | $7.59 | +5.9% | +8.1% | -3.5% | -5.2% | -0.6% | +3.4% |
| Nov 11 | Barclays | Maintains | Underweight → Underweight | — | $7.36 | $7.40 | +0.5% | +0.4% | +0.1% | -2.4% | +0.1% | -1.2% |
| Aug 15 | UBS | Maintains | Neutral → Neutral | — | $5.68 | $5.81 | +2.3% | +2.8% | -3.3% | +2.8% | -1.5% | +1.0% |
| Aug 9 | Barclays | Maintains | Underweight → Underweight | — | $5.93 | $5.76 | -2.9% | -5.6% | -1.8% | +6.2% | -2.7% | +2.8% |
| Apr 22 | Morgan Stanley | Maintains | Overweight → Overweight | — | $5.71 | $5.71 | +0.0% | +2.8% | +4.1% | +1.0% | -0.2% | +0.6% |
| Mar 6 | Jefferies | Maintains | Buy → Buy | — | $7.38 | $7.42 | +0.5% | -1.9% | -0.3% | -0.1% | -1.7% | -3.0% |
| Mar 4 | Goldman Sachs | Maintains | Neutral → Neutral | — | $7.79 | $7.74 | -0.6% | -0.4% | -4.9% | -1.9% | -0.3% | -0.1% |
| Feb 29 | Barclays | Maintains | Underweight → Underweight | — | $8.71 | $8.83 | +1.4% | -4.1% | -6.7% | -0.4% | -4.9% | -1.9% |
| Nov 22 | Goldman Sachs | Maintains | Neutral → Neutral | — | $6.16 | $6.25 | +1.5% | +3.9% | +2.3% | +0.9% | +1.1% | +1.0% |
| Nov 17 | JP Morgan | Maintains | Neutral → Neutral | — | $6.12 | $6.17 | +0.8% | +0.8% | +0.5% | -0.6% | +3.9% | +2.3% |
| Aug 10 | JP Morgan | Maintains | Neutral → Neutral | — | $8.06 | $8.11 | +0.6% | +2.4% | -1.1% | -1.5% | -0.7% | -4.0% |
| Jul 13 | Morgan Stanley | Maintains | Overweight → Overweight | — | $8.74 | $8.74 | +0.0% | +0.5% | +6.3% | -0.9% | -0.2% | -1.3% |
| May 19 | Goldman Sachs | Maintains | Neutral → Neutral | — | $8.23 | $8.38 | +1.8% | +1.6% | -0.6% | -0.5% | -0.7% | -1.0% |
| May 11 | Morgan Stanley | Maintains | Overweight → Overweight | — | $8.26 | $8.40 | +1.7% | -0.2% | +3.6% | -1.1% | -1.9% | -1.0% |
| Jan 6 | Morgan Stanley | Upgrade | Equal Weight → Overweight | — | $4.40 | $4.70 | +6.8% | +7.3% | +5.1% | +0.4% | +2.2% | +2.6% |
| Nov 15 | Goldman Sachs | Maintains | Neutral → Neutral | — | $6.12 | $6.28 | +2.6% | -3.9% | -5.1% | -8.8% | -2.2% | -0.6% |
| Nov 14 | Cowen & Co. | Maintains | Outperform → Outperform | — | $6.15 | $6.10 | -0.8% | -0.5% | -3.9% | -5.1% | -8.8% | -2.2% |
| Aug 22 | Cowen & Co. | Maintains | Outperform → Outperform | — | $6.68 | $6.52 | -2.4% | +1.6% | +4.9% | -1.3% | -1.7% | -5.4% |
| May 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $6.20 | $6.35 | +2.4% | -6.1% | +0.2% | +8.1% | +7.8% | -2.9% |
| Mar 21 | Goldman Sachs | Maintains | Neutral → Neutral | — | $9.34 | $9.20 | -1.5% | -4.3% | +5.4% | -0.3% | +3.6% | -1.1% |
| Mar 17 | UBS | Downgrade | Buy → Neutral | — | $10.12 | $9.55 | -5.6% | -5.5% | -2.3% | -4.3% | +5.4% | -0.3% |
| Dec 17 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $9.20 | $9.20 | +0.0% | +5.0% | +0.1% | +2.2% | +0.7% | +1.5% |
| Nov 9 | JP Morgan | Downgrade | Overweight → Neutral | — | $12.83 | $10.50 | -18.2% | -24.2% | +10.6% | -5.1% | +1.3% | +2.4% |
| Sep 10 | Cowen & Co. | Maintains | Outperform → Outperform | — | $15.30 | $15.65 | +2.3% | +6.3% | -5.0% | +1.4% | -2.0% | +2.9% |
| Aug 16 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $13.45 | $13.04 | -3.0% | +2.8% | -3.3% | +0.1% | -0.9% | -3.0% |
| Jul 6 | William Blair | Maintains | Outperform → Outperform | — | $27.60 | $27.88 | +1.0% | +1.6% | +3.2% | -4.5% | +4.5% | -2.4% |
| Jul 6 | UBS | Maintains | Buy → Buy | — | $27.60 | $27.88 | +1.0% | +1.6% | +3.2% | -4.5% | +4.5% | -2.4% |
| Jul 6 | Morgan Stanley | Maintains | Overweight → Overweight | — | $27.60 | $27.88 | +1.0% | +1.6% | +3.2% | -4.5% | +4.5% | -2.4% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Apr 24, 2026 | Bessler Robert | — | Sell | 31,074 | $7.05 | $219K | 1,391,246 | +5.50% | -3.45% |
| Apr 24, 2026 | Bessler Robert | — | Sell | 31,073 | $7.05 | $219K | 1,274,448 | +5.50% | -3.45% |
| Apr 23, 2026 | Bessler Robert | — | Sell | 3,876 | $7.00 | $27K | 1,305,521 | +5.50% | -3.45% |
8-K
Unknown — 8-K Filing
LFST awarded $1.5M in equity grants to an executive, indicating confidence in leadership stability while potentially diluting existing shareholders' ownership percentages.
Mar 11
8-K
LifeStance Health Group, Inc. -- 8-K Filing
LifeStance Health Group obtained legal counsel opinion from Ropes Gray LLP regarding an unspecified transaction, likely involving securities issuance or corporate action compliance.
Mar 2
8-K · 5.02
!!! Very High
LifeStance Health Group, Inc. -- 8-K 5.02: Executive Change
Kenneth Burdick's transition from Executive Chairman to non-executive Chairman at LifeStance Health indicates a planned leadership restructuring without operational disagreement, potentially signaling management confidence and continuity.
Feb 25
Data updated apr 25, 2026 6:56pm
· Source: massive.com